Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19501003 | 0.89 | RIPK1 (0.62) | RIPK1 | |
| SCHEMBL18510345 | 0.87 | RIPK1 (0.65) | RIPK1FKBP1A | |
| SCHEMBL18510351 | 0.85 | FKBP1A (0.52) | RIPK1FKBP1A | |
| SCHEMBL878861 | 0.78 | NPSR1 (0.56) | RIPK1 | |
| SCHEMBL23170627 | 0.77 | ROCK2 (0.44) | RIPK1 | |
| SCHEMBL23170303 | 0.77 | RIPK1 (0.45) | RIPK1 | |
| SCHEMBL20180046 | 0.76 | FKBP1A (0.53) | FKBP1A | |
| SCHEMBL17881986 | 0.76 | RIPK1 (0.80) | RIPK1 | |
| SCHEMBL17881895 | 0.75 | RIPK1 (0.84) | RIPK1FKBP1A | |
| SCHEMBL17881977 | 0.75 | RIPK1 (0.84) | RIPK1FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180140577-A1 | COMPOSITIONS AND METHODS FOR TREATING ALOPECIA | DAVID WEINSTEIN CONSULTING, INC. | 2018-05-24 | — | — | US | disclosed |
| US-20170266157-A1 | METHODS FOR WOUND HEALING AND SCAR PREVENTION | DAVID WEINSTEIN CONSULTING, INC. | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180140577-A1 | COMPOSITIONS AND METHODS FOR TREATING ALOPECIA | S100A4, FKBP4, FKBP5 | RIPK1 2210/4885FKBP1A 5/4885 |
| US-20170266157-A1 | METHODS FOR WOUND HEALING AND SCAR PREVENTION | FKBP4, S100A4, FKBP14 | RIPK1 2439/4885FKBP1A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.